sirolimus and Colonic-Diseases

sirolimus has been researched along with Colonic-Diseases* in 1 studies

Other Studies

1 other study(ies) available for sirolimus and Colonic-Diseases

Article	Year
Protein-losing Enteropathy Caused by Intestinal or Colonic Lymphangiectasia Complicated by Sporadic Lymphangioleiomyomatosis: A Report of Two Cases. Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:8 This report describes two patients with sporadic lymphangioleiomyomatosis complicated by protein-losing enteropathy (PLE). Imaging studies indicated retroperitoneal lymphangioleiomyomas and abnormalities of the adjacent digestive tract. Endoscopic mucosal biopsy revealed colonic lymphangiectasia in one patient; whereas the site in the other patient was intestinal. Treatment with sirolimus led to the complete resolution of PLE within several months; additionally, marked shrinkage was observed in the lymphangioleiomyomas of both cases. These findings suggest that colonic or intestinal lymphatic congestion due to neighboring lymphangioleiomyomas was the mechanism for the development of PLE. At the time of writing this report, the beneficial effect of sirolimus has lasted for more than 3 years. Topics: Adult; Colonic Diseases; Diet Therapy; Diet, Fat-Restricted; Female; Humans; Immunosuppressive Agents; Intestinal Diseases; Lymphangiectasis; Lymphangioleiomyomatosis; Protein-Losing Enteropathies; Sirolimus; Treatment Outcome	2017

Article

Year

Protein-losing Enteropathy Caused by Intestinal or Colonic Lymphangiectasia Complicated by Sporadic Lymphangioleiomyomatosis: A Report of Two Cases.

Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:8

This report describes two patients with sporadic lymphangioleiomyomatosis complicated by protein-losing enteropathy (PLE). Imaging studies indicated retroperitoneal lymphangioleiomyomas and abnormalities of the adjacent digestive tract. Endoscopic mucosal biopsy revealed colonic lymphangiectasia in one patient; whereas the site in the other patient was intestinal. Treatment with sirolimus led to the complete resolution of PLE within several months; additionally, marked shrinkage was observed in the lymphangioleiomyomas of both cases. These findings suggest that colonic or intestinal lymphatic congestion due to neighboring lymphangioleiomyomas was the mechanism for the development of PLE. At the time of writing this report, the beneficial effect of sirolimus has lasted for more than 3 years.

Topics: Adult; Colonic Diseases; Diet Therapy; Diet, Fat-Restricted; Female; Humans; Immunosuppressive Agents; Intestinal Diseases; Lymphangiectasis; Lymphangioleiomyomatosis; Protein-Losing Enteropathies; Sirolimus; Treatment Outcome

2017